Nebulized Lidocaine and Intranasal Midazolam for NGT Insertion in Children

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Nasogastric tube (NGT) is a commonly performed procedure in the Emergency Department. Although it is not a major procedure, it is usually associated with a bad experience and cause discomfort and pain in kids. This randomized controlled double-blinded double-dummy trial aims to investigate the efficacy of local topical anesthetic and/or anxiolysis for pain/anxiety related to NGT insertion. Eligible patients are children with gastroenteritis aged 6 months to 5 years requiring NGT rehydration. The intervention are 3 arms of nebulized lidocaine with midazolam compared to nebulized midazolam alone or placebo. The primary outcome is procedure-related pain assessment using the Face, Legs, Activity, Cry, and Consolability (FLACC) scale during final NGT insertion attempt.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hamad Medical Corporation
• Treatments: Lidocaine; Midazolam

Criteria

Inclusion Criteria:

1 Previously healthy children 6 months to 5 years old presenting with AGE and some dehydration who were planned to have a nasogastric tube inserted as part of their ED treatment.

Exclusion Criteria:

1. Indication for an urgent insertion of a nasogastric tube.

2. Congenital anomalies of nose, nasopharynx, oropharynx, or oral cavity.

3. .Patients allergic to midazolam or lidocaine.

4. .Congenital Heart disease or arrhythmia.

5. .Known hepatic or renal impairment

6. .Developmentally abnormal children

7. .Patients with seizure disorder

8. .Pre-existing abnormal neurological conditions

9. .Child is taking medications known to interact with lidocaine and/or midazolam (antiarrhythmic drugs, suxamethonium, phenytoin, antidepressants, propranolol, citicoline).

10. .Known case of severe gastroesophageal reflux disease or aspiration pneumonia.